Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.1 KB
2025-12-01 08:30
Report Publication Announcement
Financial Calendar 2026
English 69.6 KB
2025-12-01 08:30
Report Publication Announcement
Financial calendar for 2026
English 1.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar 2026
Slovene 104.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar za leto 2026
Slovene 1.1 KB
2025-11-24 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.6 KB
2025-11-24 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-11-24 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 119.2 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.